** Dyne Therapeutics' DYN.O shares down 12.6% premarket to $8.32, lowest since mid-Apr, after overnight follow-on priced
** Co, which focuses on neuromuscular diseases, late Mon said sold ~24.2 mln shares at $8.25 for $200 mln gross proceeds
** Offering priced at 13.3% discount to last sale
** It intends to net offering proceeds to fund ongoing clinical development of its product candidates, per the prospectus
** Also late Mon, Waltham, Massachusetts-based firm said it secured up to $275 mln in debt financing from Hercules Capital
** Morgan Stanley, Jefferies, Stifel and Guggenheim are jt bookrunners for the offering
** With ~113.7 mln shares outstanding, DYN has $1.1 bln market cap
** On Jun 17, DYN shares fell 21% to close at $10.86 after co revised timelines for its genetic disorder therapy following meeting with the FDA
** Through Mon, stock has shed ~60% YTD
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。